RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > EMA to Focus on Pharmacovigilance, Counterfeiting

EMA to Focus on Pharmacovigilance, Counterfeiting

Posted 22 February 2012 | By

According to a report by PMLIVE Intelligence Online, the European Medicines Agency (EMA) is setting its sights on new pharmacovigilance laws and fighting counterfeit medicines. 

The goals are outlined in the new EMA Work Programme 2012, which also outlines some cost-cutting measures for the current year. Despite these reductions, the EMA is expecting to increase its focus on the areas of pharmacovigilance and anti-counterfeiting.

The report states these efforts are part of the EMA's "Road Map to 2015," which was launched in 2010.

Read more:
PMLIVE Intelligence Online: EMA to Focus on Pharmacovigilance and Combating Counterfeits in 2012

Regulatory Focus newsletters

All the biggest regulatory news and happenings.